Clinical trials: Adalimumab
Ankylosing Spondylitis
A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira
A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira
- Trial name
- NCT04135508
- Testing
- BAT1406, Humira
- Volunteers
- 554 people
- Sponsor
- Bio-Thera Solutions
Uveitis
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
This study evaluates the long- term safety and effectiveness of adalimumab in participants with non-infectious intermediate-, posterior-, or pan-uveitis in daily practice in Japan.
- Trial name
- NCT02916017
- Where
- 39 sites in Japan
- Volunteers
- 259 people
- Sponsor
- AbbVie
Severe Plaque Psoriasis in Chinese Children
A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical study of adalimumab. The project plans to enrol 30 participants and aims to evaluate the efficacy and safety of adalimumab in Chinese children with plaque psoriasis, with the primary endpoint…
- Trial name
- NCT07529925
- Testing
- Adalimumab Solution for Injection
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Takayasu Arteritis, Tocilizumab
A Pilot Study in Severe Patients With Takayasu Arteritis.
Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe.
- Conditions
- Takayasu Arteritis, Tocilizumab, Adalimumab, Treatment
- Trial name
- NCT04300686
- Testing
- Tocilizumab, Adalimumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Ulcerative Colitis
Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis
This study assesses the long-term safety and efficacy of adalimumab in pediatric subjects with ulcerative colitis.
- Trial name
- NCT02632175
- Testing
- Adalimumab
- Where
- 16 sites in United States, Japan and 4 more
- Volunteers
- 59 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa (HS)
Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa
The objective of this study is to evaluate the long-term safety and effectiveness of Humira in patients with Hidradenitis Suppurativa (HS) in real-world clinical practice in Japan.
- Trial name
- NCT03894956
- Where
- 37 sites in Japan
- Volunteers
- 46 people
- Sponsor
- AbbVie
Netherton Syndrome
Clinical Trial Using Humira in Netherton Syndrome
The main objective of this studies therapeutic : to determine the effect of Adalimumab (HumiraR) on clinical inflammatory manifestations of patients with Netherton syndrome after 3 months of treatment , with a post treatment…
- Trial name
- AntiTNF-SN (NCT02113904)
- Testing
- Adalimumab
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
This is a single-arm, multi-center, prospective cohort study (post-marketing observational study). The observation period for each participant is 48 weeks.
- Trial name
- NCT01346488
- Volunteers
- 2,088 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ulcerative Colitis
Prognosis in UC After First Biological
To study the long-term clinical outcome of patients with ulcerative colitis treated with first trial of biological therapy.
- Trial name
- biological (NCT05530122)
- Testing
- infliximab, adalimumab, golimumab, vedolizumab, ustekinumab
- Volunteers
- 192 people
- Sponsor
- Tampere University Hospital
Mucopolysaccharidosis I, Mucopolysaccharidosis II
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease…
- Conditions
- Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
- Trial name
- NCT03153319
- Testing
- Adalimumab Injection [Humira], Saline Solution for Injection
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
IBD
Combination Therapy With Two Biologicals
The efficacy and safety of dual biological therapy.
- Trial name
- Combi (NCT05135221)
- Testing
- dual biological therapy
- Where
- Finland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tampere University Hospital
Juvenile Rheumatoid Arthritis
Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis
To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese children with Polyarticular Juvenile Rheumatoid Arthritis
- Trial name
- NCT00690573
- Testing
- Adalimumab
- Where
- 12 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Abbott
Crohn's Disease
Reduce Risk for Crohn's Disease Patients
The purpose of this study is to compare the effectiveness of weekly subcutaneously administered Methotrexate for maintaining relapse-free sustained steroid/Enteral Nutrition -free 1-year remission compared with: daily oral…
- Trial name
- RCT (NCT02852694)
- Testing
- Methotrexate, Adalimumab, Azathioprine / 6 Mercaptopurine
- Where
- France
- Volunteers
- 192 people
- Sponsor
- PIBD-Net
Uveitis
Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis
The aim of this study is to determine the efficacy and safety of ADA plus MTX for the treatment in non-infectious pediatric panuveitis.
- Trial name
- NCT04588818
- Testing
- Adalimumab plus Methotrexate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Polyarticular Juvenile Arthritis
A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®)
The objective of this study is to assess persistence, adherence and changes in disease activity in the children population of juvenile arthritis patients treated with adalimumab (HUMIRA®) in the routine clinical settings in the…
- Trial name
- PETITE (NCT03383263)
- Where
- 14 sites in Russia
- Volunteers
- 70 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Real World Study of a Adalimumab Biosimilar (Geleli) in Rheumatoid Arthritis
The purpose of this multicenter, prospective, Observational study is to assess the Efficacy and Safety of an Adalimumab Biosimilar (Geleli) in Rheumatoid Arthritis in the real world setting.
- Trial name
- NCT05240859
- Testing
- Geleli
- Where
- China
- Volunteers
- 1,600 people
- Sponsor
- Peking University People's Hospital
Psoriasis
Spanish Registry of Systemic Treatments in Psoriasis
The purpose of Biobadaderm is a to study the safety of systemic therapy in psoriasis.
- Trial name
- Biobadaderm (NCT02075697)
- Where
- 13 sites in Spain
- Volunteers
- 3,500 people
- Sponsor
- Fundación Academia Española de Dermatología
Rheumatoid Arthritis
Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice
This was a single-arm, multicenter, open label, prospective cohort study (post-marketing observational study) to determine the effectiveness and safety of adalimumab in combination with high-dose methotrexate (≥12 mg/week) in…
- Trial name
- NCT01736189
- Testing
- Adalimumab
- Volunteers
- 346 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Crohn's Disease, Ulcerative Colitis (UC)
A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma
To collect and store blood and biopsy samples obtained from CD or UC patients exposed to adalimumab and diagnosed with Hepatosplenic T-cell Lymphoma (HSTCL), for the purpose of identifying potential biomarkers and genetic…
- Conditions
- Crohn's Disease, Ulcerative Colitis (UC), Hepatosplenic T-Cell Lymphoma
- Trial name
- HSTCL (NCT02087878)
- Where
- Italy
- Sponsor
- AbbVie
Juvenile Idiopathic Arthritis
Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use
The main objective of this study is to evaluate the safety of adalimumab in patients 2 to < 4 years of age or ≥ 4 years of age weighing < 15 kg, with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA)…
- Trial name
- NCT00775437
- Testing
- Adalimumab
- Volunteers
- 32 people
- Sponsor
- AbbVie (prior sponsor, Abbott)